Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

New Delhi:  Aurobindo Pharma Ltd on Tuesday said it has set April 23 as the opening date for its Rs 800 crore buyback offer.

The closing date for the buyback is April 29, Aurobindo Pharma said in a regulatory filing.

Earlier on April 6, the company’s board had approved buyback of up to 54,23,728 fully paid-up equity shares having a face value of Re 1 each at a price of Rs 1,475 per share for an aggregate amount up to Rs 800 crore on a proportionate basis through the tender offer route.

The company has set April 17 as the record date for determining the entitlement and the names of equity shareholders who would be eligible to participate in the buyback.

The buyback size constitutes 3.93 per cent and 2.62 per cent of the aggregate of the total paid-up equity share capital and free reserves (including securities premium) of the company as per the audited standalone and consolidated financial statements of the Company as at March 31, 2025, respectively, the filing said.

In its letter to shareholders, Aurobindo Pharma said the buyback will help it reward shareholders and enhance the overall return to them, while it is expected to improve earnings per share and other key ratios such as return on net worth and return on assets over a period of time.

The buyback will not result in a change in control or otherwise affect the existing management structure of the company, it added.

Related Posts

Annovis Bio receives US patent covering new crystalline form of buntanetap

Annovis Bio, Inc. (Annovis), a phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), announced that…

Bengaluru: Medical devices worth ₹13.79 lakh seized in enforcement drive

The enforcement wing of Karnataka’s Food Safety and Drugs Control Department has seized medical devices and consumables worth ₹13.79 lakh from two establishments in Bengaluru’s Cottonpet area for alleged violations…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Annovis Bio receives US patent covering new crystalline form of buntanetap

Annovis Bio receives US patent covering new crystalline form of buntanetap

Bengaluru: Medical devices worth ₹13.79 lakh seized in enforcement drive

Bengaluru: Medical devices worth ₹13.79 lakh seized in enforcement drive

Yashoda Medicity Unveils T-Shirts & Finisher Medals ahead of Yashoda Half Marathon 4.0

Yashoda Medicity Unveils T-Shirts & Finisher Medals ahead of Yashoda Half Marathon 4.0

PharmEasy sees need for early prevention and regular screening to stall risk of diabetes

PharmEasy sees need for early prevention and regular screening to stall risk of diabetes

Saudi pharma company seeks Indian manufacturers for product registration, commercialisation in Saudi Arabia

Saudi pharma company seeks Indian manufacturers for product registration, commercialisation in Saudi Arabia

From ‘Kidney Care’ to ‘Liver Detox’, Uttar Pradesh bans misleading supplement labels

From ‘Kidney Care’ to ‘Liver Detox’, Uttar Pradesh bans misleading supplement labels